Medpace Holdings Inc (MEDP) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.

Total Revenue Chart for Medpace Holdings Inc

Medpace Holdings Inc (MEDP) revenue for FY2025 was USD 2.5B, a 20.0% change from FY2024. Medpace Holdings Inc's revenue grew from USD 272.9M in 2013 to USD 2.5B in 2025 (827.2% over 12 years). Earnings per share moved from USD -0.53 in 2014 to USD 7.29 in 2022. Revenue compound annual growth rate: 5-year CAGR of 22.3%, 10-year CAGR of 21.6%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$16.83B
Implied Share Price
$602.90
Enterprise Value
$16.84B
Revenue (TTM)
$2.78B
EBITDA
$611.20M
Profit Margin
17.67%
Trailing P/E
35.40
Forward P/E
31.95
Price/Book (MRQ)
39.70
Price/Sales (TTM)
6.05
EV/EBITDA
27.56
EV/Revenue
6.05
Dividend Yield
—
Book Value
$15.54
Free Cash Flow (FY2025)
$681.87M
Free Cash Flow Yield
4.05%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.